Imatinib mesylate treatment of nephrogenic systemic fibrosis

Arthritis and Rheumatism

Volumn 58, Issue 8, 2008, Pages 2543-2548

  Kay, Jonathan ^a   High, Whitney A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; IMATINIB; PROCOLLAGEN;

AGED; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; DRUG DOSE INCREASE; GONIOMETRY; HUMAN; HUMAN TISSUE; JOINT CONTRACTURE; KNEE FUNCTION; MALE; MODIFIED RODNAN SKIN THICKNESS SCORE; NEPHROGENIC SYSTEMIC FIBROSIS; PASSIVE MOVEMENT; PRIORITY JOURNAL; RANGE OF MOTION; SCORING SYSTEM; SKIN BIOPSY; SKIN FIBROSIS; SKIN MANIFESTATION; SKIN TETHERING; SKINFOLD; SYSTEMIC DISEASE;

AGED; FIBROSIS; HUMANS; KIDNEY DISEASES; KNEE JOINT; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

EID: 49449100183     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23696     Document Type: Article

References (21)

1. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007;56:3433-41.
2. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
3. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004;351:2219-27.
4. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum 2004;50:2660-6.
5. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [published erratum appears in Nephrol Dial Transplant 2006;21:1745]. Nephrol Dial Transplant 2006;21:1104-8.
6. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-6.
7. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:710-2.
8. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-93.
9. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007;143:1025-30.
10. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16.
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat Med 1996;2:561-6.
12. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
13. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
14. Riaz Y, Cook HT, Wangoo A, Glenville B, Shaw RJ. Type 1 procollagen as a marker of severity of scarring after sternotomy: effects of topical corticosteroids. J Clin Pathol 1994;47:892-9.
15. Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of imatinib mesylate in end stage renal disease: a case study. Cancer Chemother Pharmacol 2005;56:358-60.
16. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
17. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.
18. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-7.
19. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
20. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000;275:39027-31.
21. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.